Literature DB >> 11216706

Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.

M E Silfen1, J H Garvin, A P Hays, H S Starkman, G S Aranoff, L S Levine, N A Feldstein, B Wong, S E Oberfield.   

Abstract

We report a 15-year-old boy who had isolated central diabetes insipidus initially diagnosed at age 11 years. A brain magnetic resonance imaging (MRI) was normal at the time. At age 12 years, growth hormone (GH) testing was performed because of a decline in linear growth rate and demonstrated GH deficiency. After a repeat normal brain MRI, GH therapy was begun. Three years later, hormonal testing revealed prepubertal gonadotropins and low testosterone levels, free thyroxine index, and morning cortisol levels. Repeat brain MRI demonstrated a 9-mm enhancing lesion in the region of the pituitary stalk. The pathologic diagnosis was that of a high-grade malignant B-cell lymphoma, suggestive of Burkitt Lymphoma. Growth hormone therapy has not been associated with an increased incidence of lymphoma. This report underscores the need for vigilance in follow-up brain imaging and hormonal evaluation in children with diabetes insipidus, especially those with evolving anterior hormone deficiencies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11216706     DOI: 10.1097/00043426-200102000-00013

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  11 in total

1.  Primary pituitary lymphoma in an immunocompetent patient: a rare clinical entity.

Authors:  Yaxiong Li; Yuekang Zhang; Jianguo Xu; Ni Chen
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

2.  Symptomatic hypopituitarism revealing primary suprasellar lymphoma.

Authors:  Zouhour Fadoukhair; Mounia Amzerin; Nabil Ismaili; Rhizlane Belbaraka; Rachida Latib; Yassir Sbitti; Hind M'rabti; Saber Boutayeb; Mohammed Ichou; Hassan Errihani
Journal:  BMC Endocr Disord       Date:  2010-11-29       Impact factor: 2.763

3.  Case report. Primary hypothalamic third ventriclular Burkitt's lymphoma: a case report with emphasis on differential diagnosis.

Authors:  M Takasu; S Takeshita; N Tanitame; A Tamura; M Mori; M Fujihara; K Ito
Journal:  Br J Radiol       Date:  2010-02       Impact factor: 3.039

4.  Pituitary stalk thickening and primary central nervous system lymphoma.

Authors:  M Capra; D Wherrett; S Weitzman; P Dirks; C Hawkins; E Bouffet
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 5.  Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma.

Authors:  Mutsuko Yasuda; Nobu Akiyama; Sachio Miyamoto; Masahiro Warabi; Yumiko Takahama; Mari Kitamura; Fumiatsu Yakushiji; Hiroyuki Kinoshita
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

6.  Primary central nervous system burkitt lymphoma with non-immunoglobulin heavy chain translocation in right ventricle: case report.

Authors:  Ming Jiang; Jiang Zhu; Yong-song Guan; Li-qun Zou
Journal:  Pediatr Hematol Oncol       Date:  2011-05-26       Impact factor: 1.969

Review 7.  Endocrinopathies in survivors of childhood neoplasia.

Authors:  Nicole Barnes; Wassim Chemaitilly
Journal:  Front Pediatr       Date:  2014-09-23       Impact factor: 3.418

8.  Primary lymphoma of the pituitary gland: an unusual cause of hemianopia in an immunocompetent patient.

Authors:  Pg Rainsbury; A Mitchell-Innes; Nj Clifton; Hs Khalil
Journal:  JRSM Short Rep       Date:  2012-08-17

9.  Malignant lymphoma in the parasellar region.

Authors:  Takao Koiso; Hiroyoshi Akutsu; Shingo Takano; Tetsuya Yamamoto; Eiichi Ishikawa; Yasushi Okoshi; Akira Matsumura
Journal:  Case Rep Med       Date:  2014-02-10

10.  Primary Pituitary Lymphoma in Immunocompetent Patients: A Report on Two Case Studies and the Review of Literature.

Authors:  Lian Duan; Jie Liu; Yan Zhang; Lijia Cui; Xiao Zhai; Boju Pan; Lin Lu; Hui Pan; Yong Yao; Huijuan Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-04       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.